Renaissance Technologies (RenTech)'s KROS Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 453,482 shares of Keros Therapeutics, Inc. (KROS) worth $5.01 M, representing 0.01% of the portfolio. First purchased in 2020-Q2, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in KROS, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 436,986 shares. Largest reduction occurred in Q1 2026, reducing 138,204 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Keros Therapeutics (KROS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Keros Therapeutics (KROS) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -138,204 | Reduce 23.36% | 453,482 | $11.04 |
| Q4 2025 | +436,986 | Add 282.47% | 591,686 | $20.36 |
| Q3 2025 | +8,100 | Add 5.53% | 154,700 | $15.82 |
| Q2 2025 | +146,600 | New Buy | 146,600 | $13.35 |
| Q3 2024 | -14,300 | Sold Out | 0 | $0.00 |
| Q2 2024 | +14,300 | New Buy | 14,300 | $45.70 |
| Q4 2023 | -43,700 | Sold Out | 0 | $0.00 |
| Q3 2023 | -24,700 | Reduce 36.11% | 43,700 | $31.88 |
| Q2 2023 | -52,700 | Reduce 43.52% | 68,400 | $0.04 |
| Q1 2023 | +29,200 | Add 31.77% | 121,100 | $0.04 |
| Q4 2022 | -5,300 | Reduce 5.45% | 91,900 | $0.05 |
| Q3 2022 | -44,500 | Reduce 31.40% | 97,200 | $37.62 |
| Q2 2022 | +136,400 | Add 2573.58% | 141,700 | $27.63 |
| Q1 2022 | +5,300 | New Buy | 5,300 | $54.34 |
| Q4 2021 | -24,572 | Sold Out | 0 | $0.00 |
| Q3 2021 | +24,572 | New Buy | 24,572 | $39.56 |
| Q1 2021 | -10,100 | Sold Out | 0 | $0.00 |
| Q4 2020 | -7,600 | Reduce 42.94% | 10,100 | $70.50 |
| Q3 2020 | +11,400 | Add 180.95% | 17,700 | $38.59 |
| Q2 2020 | +6,300 | New Buy | 6,300 | $37.46 |
Renaissance Technologies (RenTech)'s Keros Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Keros Therapeutics, Inc. (KROS) in Q2 2020, acquiring 6,300 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Keros Therapeutics, Inc. (KROS) for 20 quarters since Q2 2020.
Renaissance Technologies (RenTech)'s largest addition to Keros Therapeutics, Inc. (KROS) was in Q4 2025, adding 591,686 shares worth $12.05 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 453,482 shares of Keros Therapeutics, Inc. (KROS), valued at approximately $5.01 M.
As of the Q1 2026 filing, Keros Therapeutics, Inc. (KROS) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Keros Therapeutics, Inc. (KROS) was 591,686 shares, as reported at the end of Q4 2025.